Patients with locally advanced or metastatic BCC show enduring responses to the hedgehog pathway inhibitor sonidegib, final results from the BOLT study have shown. But high rates of musculoskeletal side effects and withdrawals from treatment suggest a need to manage patient expectations and use intermittent therapy, say study investigators. Releasing the final 42-month follow up ...
Durable responses seen in advanced BCC with sonidegib
By Michael Woodhead
25 Sep 2019